Russ McMahen

Russ McMahen has 30 years of industry experience specializing in the development of solid, liquid and suspension dosage forms. Mr. McMahen is the co-inventor of the DTRS® and RDIM™ ion exchange delivery technologies that were utilized to develop the modified release microparticles that are used in Aytu BioPharma’s products. Prior to joining Aytu BioPharma upon the merger with Neos Therapeutics in 2021, Mr. McMahen held various positions including Senior Vice President, Research & Development, Executive Vice President of Operations and Vice President of Scientific Affairs. Prior to joining Neos, Mr. McMahen served at Zenith/Goldline Laboratories which was subsequently acquired by Ivax Pharmaceuticals. He has a B.S. in Chemical Engineering from Louisiana Tech University.